Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKSNASDAQ:FOLDNASDAQ:IONSNASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$28.75-0.9%$30.12$22.90▼$36.45$4.76B0.441.73 million shs1.12 million shsFOLDAmicus Therapeutics$6.16+3.4%$6.17$5.51▼$12.65$1.88B0.513.16 million shs3.12 million shsIONSIonis Pharmaceuticals$42.98-1.4%$35.24$23.95▼$52.34$6.84B0.231.60 million shs1.34 million shsMNKDMannKind$3.61-0.4%$4.22$3.52▼$7.63$1.09B0.962.43 million shs1.74 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-0.21%-8.85%-4.36%+18.65%FOLDAmicus Therapeutics0.00%+3.79%+0.90%-17.93%-37.26%IONSIonis Pharmaceuticals0.00%+7.99%+22.42%+58.66%-5.75%MNKDMannKind0.00%-4.12%-17.13%-23.95%-28.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.9378 of 5 stars4.43.00.04.23.42.51.9FOLDAmicus Therapeutics3.7007 of 5 stars3.41.00.04.30.60.01.9IONSIonis Pharmaceuticals4.6663 of 5 stars4.42.00.03.03.23.30.6MNKDMannKind2.6327 of 5 stars3.61.00.00.00.81.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.83Moderate Buy$40.0039.13% UpsideFOLDAmicus Therapeutics 2.70Moderate Buy$16.22163.56% UpsideIONSIonis Pharmaceuticals 2.78Moderate Buy$58.2535.53% UpsideMNKDMannKind 3.29Buy$10.33186.64% UpsideCurrent Analyst Ratings BreakdownLatest MNKD, IONS, ALKS, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.006/26/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.006/17/2025ALKSAlkermesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$33.00 ➝ $42.006/12/2025IONSIonis PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$45.00 ➝ $48.005/28/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy$45.005/20/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/13/2025ALKSAlkermesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/2/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/2/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$39.00 ➝ $40.005/2/2025ALKSAlkermesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$38.00 ➝ $41.005/2/2025FOLDAmicus TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.04$2.64 per share10.88$9.05 per share3.18FOLDAmicus Therapeutics$528.29M3.59N/AN/A$0.65 per share9.47IONSIonis Pharmaceuticals$705M9.70N/AN/A$3.73 per share11.52MNKDMannKind$285.50M3.84$0.14 per share25.94($0.29) per share-12.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0913.7620.991.7923.30%27.52%17.98%7/23/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.09N/A14.31N/A-5.41%4.67%1.05%8/14/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$2.99N/AN/AN/A-63.65%-91.85%-15.77%7/30/2025 (Estimated)MNKDMannKind$27.59M$0.1036.0515.67N/A10.12%-32.41%10.85%8/6/2025 (Estimated)Latest MNKD, IONS, ALKS, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/23/2025Q2 2025ALKSAlkermes$0.42N/AN/AN/A$343.20 millionN/A5/8/2025Q1 2025MNKDMannKind$0.03$0.04+$0.01$0.04$75.86 million$78.35 million5/1/2025Q1 2025ALKSAlkermes$0.32$0.13-$0.19$0.13$307.53 million$306.51 million4/30/2025Q1 2025IONSIonis Pharmaceuticals-$1.07-$0.93+$0.14-$0.93$144.31 million$132.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.332.92FOLDAmicus Therapeutics2.023.342.47IONSIonis Pharmaceuticals2.639.669.62MNKDMannKindN/A2.362.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%FOLDAmicus TherapeuticsN/AIONSIonis Pharmaceuticals93.86%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%FOLDAmicus Therapeutics2.20%IONSIonis Pharmaceuticals2.60%MNKDMannKind2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800164.90 million157.65 millionOptionableFOLDAmicus Therapeutics480307.93 million301.16 millionOptionableIONSIonis Pharmaceuticals1,069159.16 million155.02 millionOptionableMNKDMannKind400303.93 million295.73 millionOptionableMNKD, IONS, ALKS, and FOLD HeadlinesRecent News About These CompaniesMannKind (NASDAQ:MNKD) Hits New 1-Year Low - What's Next?July 1, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Rating Lowered to Hold at Wall Street ZenJune 28, 2025 | americanbankingnews.comMannKind (NASDAQ:MNKD) Rating Lowered to "Hold" at Wall Street ZenJune 27, 2025 | marketbeat.comHealth Rounds: Inhaled insulin as good as injection for children at mealtimeJune 25, 2025 | reuters.comMannKind (NASDAQ:MNKD) Stock Price Down 5.6% - What's Next?June 25, 2025 | marketbeat.comLeerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy RatingJune 24, 2025 | insidermonkey.comMannKind Corporation (NASDAQ:MNKD) Given Average Recommendation of "Buy" by BrokeragesJune 24, 2025 | marketbeat.comMannKind FY2026 EPS Forecast Decreased by Leerink PartnrsJune 19, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Reaches New 1-Year Low - Should You Sell?June 17, 2025 | marketbeat.comMannKind’s Afrezza: A Significantly Undervalued Investment Opportunity with Promising Clinical DataJune 16, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Buy" RatingJune 14, 2025 | marketbeat.comInsider Selling: MannKind Co. (NASDAQ:MNKD) Director Sells 64,085 Shares of StockJune 11, 2025 | insidertrades.comInsider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD)June 10, 2025 | gurufocus.comMannKind Co. (NASDAQ:MNKD) Director Sells 64,085 SharesJune 10, 2025 | marketbeat.comMannKind’s Strategic Growth Potential and Market Positioning: A Buy RecommendationJune 10, 2025 | tipranks.comMannKind (NASDAQ:MNKD) Sets New 1-Year Low - Time to Sell?June 10, 2025 | marketbeat.comCantor Fitzgerald Estimates MannKind FY2026 EarningsJune 10, 2025 | marketbeat.comMannKind Corp (MNKD) to Showcase Inhaled Insulin at ADA's 85th Scientific Sessions | MNKD stock newsJune 9, 2025 | gurufocus.comMannKind Corporation to Showcase Inhaled Insulin Innovations at ADA's 85th Scientific SessionsJune 9, 2025 | quiverquant.comQMannKind to present inhaled insulin study at ADA eventJune 9, 2025 | investing.comMannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23June 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!By Thomas Hughes | June 16, 2025View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!Analysts Supercharge AMD Stock Ahead of Q2 AI CatalystBy Thomas Hughes | June 26, 2025View Analysts Supercharge AMD Stock Ahead of Q2 AI CatalystAs Oil Prices Rebound, These Stocks Could Fuel the Next RallyBy Sarah Horvath | June 9, 2025View As Oil Prices Rebound, These Stocks Could Fuel the Next Rally2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge Potential3 Growth Stocks Too Small for Institutions to BuyBy Gabriel Osorio-Mazilli | June 19, 2025View 3 Growth Stocks Too Small for Institutions to BuyMNKD, IONS, ALKS, and FOLD Company DescriptionsAlkermes NASDAQ:ALKS$28.75 -0.25 (-0.86%) Closing price 07/3/2025 03:26 PM EasternExtended Trading$28.75 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Amicus Therapeutics NASDAQ:FOLD$6.16 +0.21 (+3.45%) Closing price 07/3/2025 03:39 PM EasternExtended Trading$6.08 -0.08 (-1.22%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ionis Pharmaceuticals NASDAQ:IONS$42.98 -0.61 (-1.40%) Closing price 07/3/2025 02:44 PM EasternExtended Trading$42.64 -0.34 (-0.79%) As of 07/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.MannKind NASDAQ:MNKD$3.60 -0.02 (-0.41%) Closing price 07/3/2025 03:48 PM EasternExtended Trading$3.61 +0.00 (+0.14%) As of 07/3/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
